Author Archives: Federico Pollano

Early Stage Development of Advanced Formulations in the Drug Development Process Provides Competitive Advantages: Survey Predicts That Drug Product Formulation Recognition and Budgets Will Increase Significantly

New antibody formats and aggregate-prone, subcutaneously administered protein therapeutics present biopharmaceutical companies with major challenges regarding protein stability and aggregation. At the same time, protein stability often is not given enough attention in early stages of development. Protein aggregation reduces drug activity so that increasing doses are needed to achieve the same desired effect. Even worse, protein aggregates can induce immunogenecity that endangers patients and compromises product approval. A market study presented for the first time at the Bio-Europe 2018…

A World-Class Biopharmaceutical CDMO

Rentschler Biopharma SE — located in Laupheim, Germany — is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company’s clients include innovative biotech companies and major pharmaceutical companies around the world. Rentschler Biopharma has long-standing experience and proven excellence as a solution partner of choice. A top-notch quality management system, well-established operational excellence, and advanced technologies ensure product quality at each development and manufacturing step. Rentschler Biopharma is a family-owned company with over 850…